Sulbactam

Sulbactam
Clinical data
AHFS/Drugs.comInternational Drug Names
MedlinePlusa693021
Routes of
administration
Intravenous, intramuscular
ATC code
Legal status
Legal status
  • UK: POM (Prescription only)
Pharmacokinetic data
Protein binding29%
Elimination half-life0.65–1.20 hrs
ExcretionMainly kidneys (41–66% within 8 hrs)
Identifiers
  • (2S,5R)-3,3-Dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid 4,4-dioxide
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.063.506 Edit this at Wikidata
Chemical and physical data
FormulaC8H11NO5S
Molar mass233.24 g·mol−1
3D model (JSmol)
Melting point148 to 151 °C (298 to 304 °F)
  • O=S2(=O)C([C@@H](N1C(=O)C[C@H]12)C(=O)O)(C)C
  • InChI=1S/C8H11NO5S/c1-8(2)6(7(11)12)9-4(10)3-5(9)15(8,13)14/h5-6H,3H2,1-2H3,(H,11,12)/t5-,6+/m1/s1 checkY
  • Key:FKENQMMABCRJMK-RITPCOANSA-N checkY
  (verify)

Sulbactam is a β-lactamase inhibitor. This drug is given in combination with β-lactam antibiotics to inhibit β-lactamase, an enzyme produced by bacteria that destroys the antibiotics.[1]

It was patented in 1977 and approved for medical use in 1986.[2]

  1. ^ Totir MA, Helfand MS, Carey MP, Sheri A, Buynak JD, Bonomo RA, Carey PR (August 2007). "Sulbactam forms only minimal amounts of irreversible acrylate-enzyme with SHV-1 beta-lactamase". Biochemistry. 46 (31): 8980–8987. doi:10.1021/bi7006146. PMC 2596720. PMID 17630699.
  2. ^ Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 492. ISBN 9783527607495.